Rocket Pharma Scores Fast-Track Voucher for Kids' Rare Disease Drug
Published Date: 4/2/2026
Notice
Summary
The FDA just gave Rocket Pharmaceuticals a special priority review voucher for their rare pediatric disease treatment, KRESLADI, approved on March 26, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids with rare diseases faster. It’s a big win for patients, the company, and anyone cheering for quicker cures!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Priority Review Voucher Awarded
The FDA issued a priority review voucher to Rocket Pharmaceuticals for KRESLADI, with the drug approved on March 26, 2026. The voucher can be used to obtain a faster FDA review for a future drug application under the Rare Pediatric Disease Priority Review Voucher Program.
New Pediatric Treatment Approval
A new treatment, KRESLADI (marnetegragene autotemcel), was approved on March 26, 2026 for pediatric patients with severe leukocyte adhesion deficiency-I (LAD‑I) caused by biallelic ITGB2 variants when an HLA‑matched sibling donor for transplant is not available. If you have a child with this condition, this approval adds an FDA‑approved treatment option.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-06378, Parts and Accessories Necessary for Safe Operation; Application for Exemption Renewal From Loomis Armored US, LLC
Loomis Armored US, LLC wants to renew a 5-year exemption to keep using armored trucks with welded-shut cab doors and add two extra doors behind the cab. This affects Loomis’s armored vehicle operations and could impact safety rules for these trucks. The public can comment on this request until May 4, 2026, before the government decides whether to approve it.
Next: 2026-06380, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of filings from power companies about ownership changes and a new solar project claiming special status. These updates mostly affect energy companies and could impact how they operate or report their business. If you want to comment, you’ve got until mid to late April 2026 to speak up!